Listing 13.18 Colon and Rectum Cancer in 2026

Colorectal cancer is the third most common cancer and the third leading cause of cancer death in both American men and women. The American Cancer Society projects 152,810 new colorectal cancer diagnoses (106,970 colon + 45,840 rectal) and 53,010 deaths in 2026. Overall 5-year survival is 65%: 91% for localized disease, 73% for regional, but only 16% for distant metastatic disease.

SSA Listing 13.18 covers carcinomas of the colon or rectum. The listing has four paragraphs that grant automatic disability. Unlike some cancer listings that require specific stages, 13.18 focuses on operability, nodal spread, recurrence, and histologic subtype. This walkthrough covers each paragraph, the evidence you need, the molecular testing that drives modern treatment, and how treatment residuals shape the Continuing Disability Review.

The four paragraphs of Listing 13.18

Paragraph A: Inoperable, unresectable, or recurrent

Paragraph A covers colorectal carcinoma that meets any of these conditions:

• Inoperable: patient cannot tolerate surgery due to comorbidities, poor performance status, or extensive disease
• Unresectable: disease has spread beyond what surgery can remove with clear margins - typically means locally advanced T4b invading adjacent structures beyond safe resection, or extensive metastatic disease not amenable to curative surgery
• Recurrent: cancer returned after initial curative-intent treatment, except for local recurrence controlled by additional therapy

Locally advanced rectal cancer with pelvic side wall invasion, sacral involvement below S2-S3, or extensive posterior invasion often meets the unresectable criterion. Colon cancer with peritoneal carcinomatosis, extensive liver involvement not amenable to hepatectomy, or unresectable pulmonary metastases meets Paragraph A.

Paragraph B: Metastases to or beyond the regional lymph nodes

Paragraph B qualifies colorectal cancer with metastases that have spread:

• To regional lymph nodes at diagnosis (stage III disease, T1-4 N1-N2 M0)
• Beyond regional lymph nodes to distant sites (stage IV, M1)

Regional lymph nodes for colon cancer include pericolic, mesenteric, ileocolic, right/middle/left colic, inferior mesenteric, and sigmoid nodes depending on tumor location. For rectal cancer they include perirectal, mesorectal, sigmoid mesenteric, inferior mesenteric, superior rectal, middle rectal, inferior rectal, and internal iliac nodes.

Distant sites (M1 disease) commonly include:

• Liver (most common distant site, 30-50% of metastatic cases)
• Lung (10-20%)
• Peritoneum with peritoneal carcinomatosis (10-15%)
• Distant lymph nodes (para-aortic, supraclavicular)
• Bone (5-10%)
• Brain (rare, 1-3%)

AJCC 8th edition M1 substaging: M1a single organ metastasis, M1b two or more organs, M1c peritoneal carcinomatosis with or without other organ involvement.

Paragraph C: Recurrent after total mesorectal excision or other complete resection

Paragraph C addresses rectal cancer that recurs after total mesorectal excision (TME) or colon cancer that recurs after complete surgical resection. TME is the standard of care for rectal cancer, involving en-bloc removal of the rectum with its surrounding mesorectal fascia to minimize local recurrence.

Recurrence after TME can be:

• Local (pelvic) recurrence: at the anastomosis, in the pelvic sidewall, in the pre-sacral space, or at the perineum after abdominoperineal resection
• Distant recurrence: liver, lung, peritoneum, or elsewhere
• Combined local and distant recurrence

Recurrent disease after complete resection is inherently harder to control than initial disease and generally requires salvage therapy with less curative intent. Paragraph C recognizes this by granting automatic qualification.

Paragraph D: Small-cell (oat cell) carcinoma

Paragraph D qualifies small-cell (oat cell) carcinoma of the colon or rectum, an extremely rare (less than 1% of colorectal cancers) but highly aggressive neuroendocrine variant. Diagnosis requires pathology with small-cell histology plus neuroendocrine markers (chromogranin A, synaptophysin, CD56, INSM1). Ki-67 typically greater than 55% (high-grade neuroendocrine carcinoma).

Any confirmed small-cell (oat cell) colorectal carcinoma meets 13.18D regardless of stage. Treatment follows small-cell lung cancer protocols with platinum-etoposide chemotherapy given the shared biology.

Diagnostic evidence required

SSA requires objective medical evidence for every 13.18 approval:

• Pathology report from colonoscopy biopsy, surgical resection, or metastatic site biopsy confirming adenocarcinoma (95%+ of colorectal cancers) or rare variants (mucinous adenocarcinoma 10-15% of colorectal, signet ring cell <1%, medullary, small-cell)
• Molecular testing now standard per NCCN guidelines:
  • KRAS, NRAS, BRAF mutation testing (for anti-EGFR eligibility - RAS wild-type required)
  • HER2 amplification (for HER2-directed therapy: trastuzumab + pertuzumab, trastuzumab deruxtecan)
  • MSI (microsatellite instability) or MMR (mismatch repair) status - 15% of colorectal cancers are MSI-high/dMMR (95% of Lynch syndrome CRC), qualifying for immunotherapy
  • NTRK fusions (rare, 0.2-0.5%) for larotrectinib or entrectinib eligibility
  • Tumor mutational burden (TMB) for pembrolizumab under tumor-agnostic label
• CEA (carcinoembryonic antigen) baseline and trending
• Staging imaging: CT chest/abdomen/pelvis with contrast, MRI pelvis for rectal cancer (defines T stage, mesorectal fascia involvement, extramural venous invasion), PET-CT for equivocal findings or metastatic workup
• Colonoscopy report with tumor location, size, and evaluation of remaining colon
• Surgical pathology if resected: T stage, N stage with node count, margins, lymphovascular invasion, perineural invasion, tumor deposits

The Compassionate Allowance overlay

Two colorectal cancer conditions on the 2026 CAL list:

• Small intestine cancer stage III/IV (separate listing 13.17)
• Metastatic colorectal cancer

Metastatic colorectal cancer (any stage IV) qualifies for CAL fast-track 14-30 day processing. Non-metastatic stage III disease that meets Paragraph B (nodal involvement) does not automatically get CAL flag but still meets the listing.

Modern treatment residuals for the CDR

The 3-year rule under 13.00H1 applies. Colorectal cancer treatment produces distinctive residuals from surgery, radiation, and chemotherapy.

Ostomy complications

About 30% of rectal cancer patients undergo abdominoperineal resection (APR) with permanent end colostomy. Others have temporary loop ileostomy or colostomy during rectal healing. Ostomy complications qualify under 5.06 IBD analog or the general residual analysis:

• Peristomal skin breakdown (30-40% of ostomates over time)
• Parastomal hernia (30-50% at 5+ years post-ostomy creation)
• Stomal stenosis or retraction requiring revision
• High-output ileostomy causing chronic dehydration and electrolyte imbalance (particularly with proximal ileostomy)
• Prolapse
• Odor and psychosocial impact

Oxaliplatin peripheral neuropathy

Oxaliplatin (in FOLFOX, XELOX, FOLFIRINOX regimens) causes both acute cold-induced neuropathy and chronic sensory neuropathy. Persistent grade 2 or 3 CIPN affects 20-30% of patients at 12+ months post-treatment. Grade 3 CIPN interfering with activities of daily living qualifies under 11.14 peripheral neuropathy at CDR.

5-FU and capecitabine hand-foot syndrome

Palmar-plantar erythrodysesthesia occurs in 30-60% of capecitabine users, 10-20% grade 3+. Grade 3 causes ulceration and functional impairment of hands/feet. Chronic dermatologic damage can support ongoing disability findings.

Anti-EGFR skin toxicity (cetuximab, panitumumab)

Cetuximab and panitumumab (for RAS wild-type metastatic disease) cause acneiform rash in 80-90% of patients, paronychia, hair changes, and rarely severe infusion reactions. Severe chronic dermatologic toxicity can affect quality of life significantly.

Bevacizumab (Avastin) cardiovascular effects

Bevacizumab increases hypertension (30-40%), thromboembolic events (5-10%), bleeding risk, GI perforation (1-2%), and impaired wound healing. Chronic hypertension may qualify under 4.02 heart failure at CDR if it leads to LVEF decline.

Pelvic radiation effects

Neoadjuvant or adjuvant radiation for rectal cancer (typically 45-50 Gy with 5-FU or capecitabine sensitization) causes:

• Chronic radiation proctitis with bleeding, urgency, incontinence (20-40% of survivors) - qualifies under 5.06 or 5.08 analog
• Radiation cystitis with hematuria, urinary frequency, incontinence (10-20%)
• Radiation-induced small bowel obstruction from adhesions (10-15%)
• Erectile dysfunction (near-universal in men after pelvic radiation)
• Vaginal stenosis and dyspareunia (universal in women without dilator use)
• Pelvic fractures from radiation-induced insufficiency (5-10% of long-term survivors)
• Fecal incontinence from sphincter fibrosis (particularly after chemoradiation + low anterior resection)

Immunotherapy for MSI-high disease

Pembrolizumab, nivolumab, and dostarlimab are FDA-approved for MSI-high/dMMR metastatic colorectal cancer. First-line pembrolizumab per KEYNOTE-177 showed superior progression-free survival vs chemotherapy. Immune-related adverse events include the same profile as other checkpoint inhibitors: hypothyroidism, adrenal insufficiency, T1DM, colitis (particularly problematic in colorectal cancer patients), hepatitis, pneumonitis. Endocrine irAEs are typically permanent.

Chronic pain

Pelvic pain from local recurrence, radiation, or nerve injury is a major long-term issue for rectal cancer survivors. Sacral or lumbosacral plexopathy from local recurrence can qualify under 11.14 peripheral neuropathy or 1.15 disorders of the skeletal spine with nerve root involvement.

Worked case examples

Case 1: Robert, 61, Georgia, stage III colon cancer

Robert underwent screening colonoscopy in February 2026 that revealed a 4 cm sigmoid mass. Biopsy: moderately differentiated adenocarcinoma. Staging CT showed no distant disease. Underwent laparoscopic sigmoidectomy: pathology T3N2a (5/18 nodes positive), moderately differentiated, negative margins. MSI stable, KRAS G12D mutation. Stage IIIB.

SSDI application filed March 2026. Listing 13.18B met (regional nodal metastases). Not CAL because non-metastatic. Approved 3 months at Georgia DDS. Started adjuvant FOLFOX for 6 months. At 4 months developed grade 3 oxaliplatin CIPN requiring dose reduction, then discontinuation. At 12 months post-diagnosis, persistent grade 2-3 CIPN in feet interfering with balance and ambulation. Continues to qualify at CDR under 11.14 plus 13.18B ongoing.

Case 2: Angela, 54, Texas, metastatic rectal cancer with MSI-high

Angela presented with rectal bleeding and change in bowel habits in January 2026. Colonoscopy showed a 6 cm circumferential rectal mass 8 cm from anal verge. Biopsy: poorly differentiated mucinous adenocarcinoma. Staging showed multiple liver metastases and mesenteric adenopathy. Molecular: MSI-high, KRAS/NRAS wild-type, BRAF wild-type, HER2 negative. Stage IVB.

SSDI application filed February 2026. Listing 13.18B met (distant metastases). CAL for metastatic colorectal triggered. Approved 15 days at Texas DDS. Started first-line pembrolizumab per KEYNOTE-177. Achieved partial response at 3 months, continued response at 12 months. Developed immunotherapy-induced hypothyroidism at 8 months (permanent, on levothyroxine).

Case 3: David, 68, Ohio, recurrent rectal cancer 4 years after TME

David had T3N1M0 mid-rectal cancer in 2022 treated with neoadjuvant chemoradiation (50.4 Gy + capecitabine), then low anterior resection with TME + diverting loop ileostomy (later reversed), then adjuvant FOLFOX for 6 months. Achieved pathologic complete response. Surveillance imaging clean through 2025.

In 2026, rising CEA triggered PET-CT showing new pelvic sidewall mass and 3 liver lesions. Biopsy of pelvic mass: recurrent adenocarcinoma. Distant recurrence 4 years post-treatment.

Listing 13.18C met (recurrent after TME) AND 13.18B met (distant metastases). Also CAL for metastatic. SSDI application 2026. Approved 18 days at Ohio DDS. Started FOLFIRI + bevacizumab.

What to file with your application

1. Colonoscopy report and pathology from initial biopsy
2. Surgical operative report and pathology (if resected)
3. Staging CT chest/abdomen/pelvis and MRI pelvis for rectal cases
4. Molecular testing results (KRAS, NRAS, BRAF, MSI/MMR, HER2)
5. CEA levels with trend
6. Oncology treatment plan and consultation notes
7. Any hospitalizations for treatment complications or ostomy issues
8. Current medication list

Related reading

Full section walkthrough: Section 13.00 cancer basics. Companion cancer listings: 13.05 lymphoma, 13.06 leukemia, 13.10 breast, 13.24 prostate, 13.14 lung.

Frequently asked questions

Next steps

If you were diagnosed with colorectal cancer with nodal involvement, distant metastases, or unresectable disease, file for SSDI immediately. Do not wait for surgery or chemotherapy to complete. The 5-month waiting period runs from your established onset date.